

Table of contents

Poster No.	Title	Document (=Topic)	Page
P001	AZD5153 enhances the apoptotic effects of gemcitabine on human pancreatic cancer cells via AKT/mTORC1/S6 signaling	Basic research in oncology	1
P002	Successful introduction of a point mutation into the genome of a primary colon cancer cell line using CRISPR base editing technology	Basic research in oncology	2
P003	Synthesis of a versatile mitochondria-targeting small molecule for cancer near-infrared fluorescent imaging and radio/photodynamic/photothermal synergistic therapies	Basic research in oncology	3
P004	Simple Approach to Enhance Green Tea Epigallocatechin Gallate Stability in Aqueous Solutions and its Bioavailability: Experimental and Theoretical Approaches	Basic research in oncology	4
P005	Impact of type I collagen remodeling during aging on the response to vemurafenib in BRAFV600E melanoma cells	Basic research in oncology	5
P006	Prevalence and Risk factors associated with the use of complementary and alternative medicines in Tunisian cancer patients at Salah Azaiz Institute	Basic research in oncology	6
P007	Management of buccopharyngeal mucositis induced by anticancer drugs at the Salah Azaiz institute	Basic research in oncology	7
P008	Containment assessment of five commercially available closed system transfer devices (CSTDs) using the 2016 draft NIOSH performance protocol and 2.5% v/v 2-Phenoxyethanol (2-POE) as challenge agent	Basic research in oncology	8
P009	Impact of the 2019 coronavirus pandemic on cancer treatment in the Calabria Region, Italy	Basic research in oncology	9
P010	TAS-102 WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER	Basic research in oncology	10
P011	Herceptin® and trazimera® immunogenicity in the HER2+ breast cancer treatment	Basic research in oncology	11
P012	Adherence of anti-emetic prophylactic regimes to international guidelines and incidence of chemotherapy-induced	Basic research in oncology	12

	nausea and vomiting in patients of Cancer Institute, Tehran, Iran		
P013	Adherence to Intravenous Chemotherapy in Tunisian cancer patients at Salah Azaiez institute	Basic research in oncology	13
P014	Advanced Microscopical Non-Invasive Examination of the Supposed Migrastatics for Impact on In Vitro Cell Migration	Basic research in oncology	14
P015	Palbociclib associated neutropenia in clinical practice	Clinical evaluation	1
P016	The challenge of rectal cancer survivors: Dealing with low anterior resection syndrome	Clinical evaluation	2
P017	Docetaxel toxicity monitoring in breast cancer: evaluation of professional practices in a French Comprehensive Cancer Center	Clinical evaluation	3
P018	Relationship between toxicity and effectiveness of immunotherapy in the treatment of non-small cell lung cancer	Clinical evaluation	4
P019	Safety and efficacy of isatuximab in relapsed or refractory multiple myeloma: A Meta-analysis of 11 Clinical Trials	Clinical evaluation	5
P020	Evaluation of the transfusion practices in the hemato-oncology in Mauretania	Clinical evaluation	6
P021	Incidence Of Cisplatin-Induced Nephrotoxicity And Associated Risk Factors: Single-Center Experience	Clinical evaluation	7
P022	Real world data of alk-inhibitors in patients with advanced or metastatic non-small cell lung cancer	Clinical evaluation	8
P023	Pembrolizumab in non-small-cell lung cancer: A systematic review of real life data in Spain	Clinical evaluation	9
P024	A Review of Immune Checkpoint Inhibitor Therapy in Iceland 2019-2020: Indications and Tolerability. A follow-up study from 2018-2019.	Clinical evaluation	10
P025	Trastuzumab deruxtecan: real-life use for the treatment of advanced metastatic HER2 positive breast cancer	Clinical evaluation	11
P026	CAR-T cells out of specifications: overview in real life	Clinical evaluation	12
P027	Effectiveness of venetoclax in the treatment of chronic lymphocytic leukemia: from evidence to experience.	Clinical evaluation	13
P028	Azacitidine and Nivolumab in relapsed/refractory angioimmunoblastic T-cell lymphoma: a promising combination	Clinical evaluation	14
P029	Frequency of measuring body weight in (sub)populations of patients with cancer treated with chemotherapy	Clinical evaluation	15

P030	Therapeutic management of advanced Hodgkin lymphoma in patients with pulmonary comorbidities	Clinical evaluation	16
P031	Real-world effectiveness and safety of pembrolizumab in patients with non-small cell lung cancer: a retrospective observational study	Clinical evaluation	17
P032	Lung immune prognostic index to predict effectiveness of first-line pembrolizumab in advanced non-small cell lung cancer	Clinical evaluation	18
P033	Results in real clinical practice of atezolizumab in urothelial cancer	Clinical evaluation	19
P034	Real-world use of carfilzomib in patients with relapsed or refractory multiple myeloma	Clinical evaluation	20
P035	Analytical, non-clinical, and pharmacokinetic biosimilarity assessment of EG12014, a proposed trastuzumab biosimilar candidate	Clinical evaluation	21
P036	CAR-T: TWO-YEAR OUTCOMES WITH AXICABTAGENE CILOLEUCEL CELLS	Clinical evaluation	22
P037	A SINGLE EXPERIENCE WITH PALBOCICLIB TOXICITY REQUIRING DOSE MODIFICATIONS AND ITS IMPACT ON THE EFFICACY	Clinical evaluation	23
P038	The use of intravenous azacitidine : an attractive alternative to be supervised	Clinical evaluation	24
P039	Gynecomastia in a male after Imatinib treatment for chronic myeloid leukemia	Clinical evaluation	25
P040	Results after discontinuation of pembrolizumab in metastatic melanoma or lung cancer patients: real-word experience.	Clinical evaluation	26
P041	Daratumumab, Lenalidomide, and Dexamethasone for relapsed and refractory Multiple Myeloma: Progression free results from a real life analysis	Clinical evaluation	27
P042	REAL WORLD EXPERIENCE OF PALBOCICLIB AND RIBOCICLIB IN COMBINATION WITH FULVESTRANT OR WITH LETROZOLE IN THE FIRST-LINE TREATMENT OF METASTATIC FEMALE BREAST CANCER HER 2-	Clinical evaluation	28
P043	Durvalumab as consolidation therapy in locally advanced unresectable non-small cell lung cancer patients	Clinical evaluation	29
P044	Managed of persistent and refractory thrombocytopenia following haematopoietic stem cell transplant	Clinical evaluation	30
P045	Good response to cemiplimab for metastatic cutaneous squamous-cell	Clinical evaluation	31

	carcinoma in patient with ulcerative pancolitis		
P046	Real-world clinical practice of first-line palbociclib use in metastatic hormone positive HER negative metastatic breast cancer and comparative with the PALOMA-2 trial	Clinical evaluation	32
P047	Pembrolizumab as first-line treatment for metastatic non-small cell lung cancer: analysis of survival in real life	Clinical evaluation	33
P048	Adverse events comparison : CAR-T cells versus bispecific antibodies	Clinical evaluation	34
P049	Treatments used in patients with metastatic bladder carcinoma	Clinical evaluation	35
P050	Effectiveness and safety of durvalumab for advanced non cell lung cancer	Clinical evaluation	36
P051	Impact of Covid-19 in patients with multiple myeloma who are candidates for autologous hematopoietic stem cell transplantation	Clinical evaluation	37
P052	Effectiveness and safety of adjuvant treatment of melanoma with checkpoint inhibitors: nivolumab and pembrolizumab.	Clinical evaluation	38
P053	Study of the frequency of Trastuzumab cardiotoxicity in patients with breast cancer HER2+ at the oncology department of Rouiba Hospital	Clinical evaluation	39
P054	Combined liposomal form of Daunorubicin/Cytarabin : assessment of tolerance, toxicity and medico-economic impact	Clinical evaluation	40
P055	Proper use of intravenous ferric carboxymaltose (FCM) in hospitalized cancer patients: a retrospective study in real clinical practice	Clinical evaluation	41
P056	Assessing Knowledge of Community Pharmacists on Cancer: A Pilot Study in Ghana	Clinical pharmacy and pharmaceutical care	1
P057	Cancer awareness among community pharmacist: a systematic review	Clinical pharmacy and pharmaceutical care	2
P058	Clinical impact assessment of pharmaceutical intervention along pharmaceutical consultation of oral therapy-treated cancer patients	Clinical pharmacy and pharmaceutical care	3
P059	Cancelled	Clinical pharmacy and pharmaceutical care	4
P060	Indication, Safety and Adherence to Oral Targeted Anticancer Medication.	Clinical pharmacy and pharmaceutical care	5
P061	Onco-hematology telepharmacy during the covid-19 pandemic: experience of two years	Clinical pharmacy and pharmaceutical care	6
P062	Optimization of oncology patient follow-up through pharmaceutical care and multidisciplinary team working.	Clinical pharmacy and pharmaceutical care	7

P063	Relation between body mass index and therapeutic response with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer	Clinical pharmacy and pharmaceutical care	8
P064	Evaluation of the use of off-label drugs in a comprehensive cancer center	Clinical pharmacy and pharmaceutical care	9
P065	Creatinine determination in platinum-based therapy only necessary once every weeks	Clinical pharmacy and pharmaceutical care	10
P066	A descriptive, observational and cross-sectional study to determine the prevalence and risks of complementary and alternative medicine use in an adult Dutch (hemato)-oncology population receiving concurrent anti-cancer treatment	Clinical pharmacy and pharmaceutical care	11
P067	Results of a 3-years multidisciplinary team including pharmaceutical care for ambulatory blood cancer patients receiving oral antineoplastic drugs	Clinical pharmacy and pharmaceutical care	12
P068	Prevalence of Cannabidiol (CBD) consumption and cancer patients' expectations in one Oncology Day-Hospital: A cross-sectional study	Clinical pharmacy and pharmaceutical care	13
P069	Efficacy and safety in evaluating of new drug-eluting method used for Transarterial chemoembolization for hepatocellular carcinoma	Clinical pharmacy and pharmaceutical care	14
P070	Review and standardization of the hydration protocol for cisplatin-based regimes in our institute	Clinical pharmacy and pharmaceutical care	15
P071	Niraparib and psychiatric disorders: incidence rate to consider in real life?	Clinical pharmacy and pharmaceutical care	16
P072	Real-life herb-drug interactions (HDI) in cancer patients: a 2-year retrospective study in a university hospital	Clinical pharmacy and pharmaceutical care	17
P073	Development and feasibility of a clinical pharmacy program integrated into early breast cancer care pathways: the 5P project	Clinical pharmacy and pharmaceutical care	18
P074	Clinical impact of pharmaceutical care in a multidisciplinary program to secure medication therapy in lymphoma patients treated by immunochemotherapy	Clinical pharmacy and pharmaceutical care	19
P075	HEALTH RESULTS OF DARATUMUMAB IN PATIENTS WITH MULTIPLE MYELOMA	Clinical pharmacy and pharmaceutical care	20
P076	EFFICACY AND SAFETY OF THE ABVD SCHEME IN CLINICAL PRACTICE: A RETROSPECTIVE STUDY IN A SPECIALTY HOSPITAL	Clinical pharmacy and pharmaceutical care	21
P077	Chimeric Antigen Receptor T Cell Therapy for Aggressive B Cell Lymphomas or Acute Lymphoblastic	Clinical pharmacy and pharmaceutical care	22

	Leukemia: Incidence and Management of Toxicity in the Real-World Setting		
P078	Effect of frailty on the efficacy of first-line pembrolizumab monotherapy for advanced non-small cell lung cancer	Clinical pharmacy and pharmaceutical care	23
P079	EFFECTIVENESS AND SAFETY OF NEW GENERATION ANTIANDROGENS IN PROSTATE CANCER	Clinical pharmacy and pharmaceutical care	24
P080	Do patients under anticancer medication know their treatments designation?	Clinical pharmacy and pharmaceutical care	25
P081	Apalutamide and enzalutamide in metastatic hormonosensitive prostate cancer: comparison of adverse effects incidence, tolerability and efficacy	Clinical pharmacy and pharmaceutical care	26
P082	Incidence, types and acceptability of pharmaceutical interventions in Salah Azaiz Institute	Clinical pharmacy and pharmaceutical care	27
P083	Dose adjustment in conditioning chemotherapy before hematopoietic stem cell transplantation in obese patients	Clinical pharmacy and pharmaceutical care	28
P084	Excluding Ranitidine of Premedication Regimens during Paclitaxel Treatment Does Not Raise the Incidence of Hypersensitivity Reactions.	Clinical pharmacy and pharmaceutical care	29
P085	Role of a hospital pharmacist in a prostate cancer multidisciplinary committee	Clinical pharmacy and pharmaceutical care	30
P086	Real-world evidence of atezolizumab in locally advanced or metastatic urothelial carcinoma	Clinical pharmacy and pharmaceutical care	31
P087	Peroral drugs in the treatment of oncological patients with short bowel syndrom	Clinical pharmacy and pharmaceutical care	32
P088	Topical therapy for the treatment of ocular neoplasia: effectiveness and security of compounded 5-fluorouracyl eye drops	Clinical pharmacy and pharmaceutical care	33
P089	The impact of clinical oncology pharmacy in a multidisciplinary healthcare team	Clinical pharmacy and pharmaceutical care	34
P090	Iatrogenic prevention of anticancer drugs: pivotal role of the pharmaceutical network city-hospital, the experience of a French departmental hospital	Clinical pharmacy and pharmaceutical care	35
P091	THE IMPACT OF COVID-19 ON MENTAL HEALTH OF HEALTH PROFESSIONALS IN ONCOLOGY PHARMACY	Clinical pharmacy and pharmaceutical care	36
P092	CDSS ALERTS FOR FLUOROPYRIMIDINE PRE-TREATMENT DPYD SCREENING (SPORE STUDY)	Clinical pharmacy and pharmaceutical care	37
P093	Pharmaceutic-oncological case reports compiled as book	Clinical pharmacy and pharmaceutical care	38

P094	Evaluation of nausea control and chemotherapy-induced vomiting in patients undergoing intravenous chemotherapy	Clinical pharmacy and pharmaceutical care	39
P095	STUDY OF INTERACTIONS WITH SECOND-GENERATION ANTIANDROGENS IN PROSTATE CANCER PATIENTS	Clinical pharmacy and pharmaceutical care	40-41
P096	Securing therapy for patients with Leukemia, Myelogenous, Chronic through pharmaceutical care in the hematology department of the Tlemcen hospital Algeria	Clinical pharmacy and pharmaceutical care	42-43
P097	Interventions by pharmacists in patient pharmaceutical care	Clinical pharmacy and pharmaceutical care	44
P098	Subcutaneous daratumumab versus intravenous daratumumab for the treatment of patients with multiple myeloma: A time, motion and cost assessment study in a general hospital	Cytotoxic drug preparation	1
P099	Evaluation of Mogamulizumab's dose-banding in an anticancer drug preparation unit	Cytotoxic drug preparation	2
P100	Transarterial chemoembolization for hepatocellular carcinoma: proposition of new drug-eluting method using a Mixture Design	Cytotoxic drug preparation	3
P101	Knowledge of the safe handling of medicine used in chemotherapy by pharmaceutical specialists in Latvia	Cytotoxic drug preparation	4
P102	Implementation of dose-banding in our hospital: ready-to-infuse bags or standardized dose batches?	Cytotoxic drug preparation	5
P103	Hazardous Drug and Antibiotic Residue Surface Contamination-Is there a need to reduce exposure?	Cytotoxic drug preparation	6
P104	Surface contamination with antineoplastic drugs over 8 years in one hospital pharmacy unit working with isolator technology	Cytotoxic drug preparation	7
P105	Process improvement strategy for preparation of immunotherapy from freeze-dried BCG in the Central pharmacy of the University Medical Centre Maribor	Cytotoxic drug preparation	8
P106	Management of Oncolytic viruses in hospital pharmacy: an experience from a French Cancer Centre	Cytotoxic drug preparation	9
P107	STABILITY OF TRIPLE INTRATHECAL STANDARDIZED PREPARATION OF METHOTREXATE, CYTARABINE AND METHYLPREDNISOLONE SODIUM SUCCINATE	Drug stability	1

P108	Study of the relevance of osmolality measurement as a criterion for evaluating drug stability	Drug stability	2
P109	Extended in-use stability of the generic nab-paclitaxel medicine Pazenir®	Drug stability	3
P110	Extended time of use of reconstituted and diluted anticancer drugs: an online software on chemical-physical stability data	Drug stability	4
P111	Predictive intrinsic stability of Elagolix (EGX), pertinent to drug storage and in-use condition	Drug stability	5
P112	Retrospective and descriptive analysis of short stability antibodies losses, prepared in French centralized preparation unit in and out of clinical trials	Drug stability	6
P113	Physicochemical and biological stability study of mogamulizumab in diluted solution	Drug stability	7
P114	Observational study of cytotoxic drugs administration practice in oncology day hospital	Organisation and management	1
P115	Outpatient administration of blinatumomab for acute lymphocytic leukemia	Organisation and management	2
P116	Environmental contamination of a dematerialized chemotherapy production unit: current situation and future prospects	Organisation and management	3
P117	Evolution of clinical trials in onco-hematology in a reference center: does it worth a dedicated structure ?	Organisation and management	4
P118	Improving healthcare organization of patients treated by anticancer oral therapy : what expectations ?	Organisation and management	5
P119	Application of a Lean Six Sigma methodology for the organization and production of chemotherapy	Organisation and management	6
P120	Best practice in Ukraine of extemporaneous drug manufacturing in personalized pharmacy center.	Organisation and management	7
P121	Risk mapping in a chemotherapy preparation unit (CPU) using a tool developed by a French regional health agency	Organisation and management	8
P122	Human Intratumoral Immunotherapy (HIT-IT) or Interventional immunotherapy: an experience from a French Cancer Center	Organisation and management	9
P123	Axitinib's distribution: between environmental impact and indirect costs	Organisation and management	10
P124	Cancelled	Other	1

P125	Instrumental radiopharmacy – a step in reduction of occupational dose at the department of nuclear medicine	Other	2
P126	PSYCHOLOGICAL IMPACT OF COVID-19 PANDEMIC IN CANCER PATIENTS AT THE INSTITUTE OF SALAH AZAIZ	Other	3
P127	Chemfort® Closed System Transfer Device (CSTD) Extends Practical In-Use Shelf Life to 28 Days After First Puncture of Non-Preserved Single-Use Vials	Other	4
P128	3D Printing of personalized medicine	Other	5
P129	Providing oncology pharmacy services during the coronavirus pandemic. French Society for Oncology Pharmacy (Société Française de Pharmacie Oncologique-SFPO) guidelines writing and evaluation	Other	6
P130	Providing oncology pharmacy services to Ukrainian refugees suffering from cancer. Elaboration of the guidelines for pharmaceutical care and information leaflets on dispensing of oral cancer drugs in the Ukrainian language provided by French Society for Oncology Pharmacy (Société Française de Pharmacie Oncologique-SFPO)	Other	7
P131	Immunity vs oncology immunotherapy	Other	8
P132	The application of STIBS in cancer gene therapy, immunooncology, clinical trials and drug production laboratories	Other	9
P133	Advancing Oncology Pharmacy Education in South Africa	Other	10
P134	Cancer treatments: A Vademecum for healthcare professionals	Other	11
P135	Increasing acceptance of annual in-house training for CMR substances: change from face-to-face to webinar	Other	12
P136	Nivolumab & Pembrolizumab: the economic impact of a fixed-dose strategy	Pharmacoeconomics	1
P137	Effectiveness and cost-effectiveness of durvalumab after chemo-radiotherapy in non-small cell lung cancer	Pharmacoeconomics	2
P138	Influence of a durvalumab use protocol based on patient weight on treatment costs	Pharmacoeconomics	3
P139	A comparison between cost perception of anticancer treatment by patients under chemotherapy and those under targeted therapy or immunotherapy in Tunisian cancer patients at Salah Azaiez institute	Pharmacoeconomics	4
P140	ECONOMIC IMPACT OF FIXED-DOSE NIVOLUMAB AND	Pharmacoeconomics	5

	PEMBROLIZUMAB IN A ONCOLOGY INSTITUTION		
P141	Individual dosing of carboplatin according to five formula used in a cohort of patients with ovarian cancer in real life	Pharmacokinetics and therapeutic drug monitoring	1
P142	Day +7 asparaginase activity as a predictive value Ila pediatric	Pharmacokinetics and therapeutic drug monitoring	2
P143	Pharmacokinetics of trastuzumab in patients with HER2+ gastric cancer	Pharmacokinetics and therapeutic drug monitoring	3
P144	DPYD gene mutation frequency in oncology patients in a tertiary hospital	Pharmacokinetics and therapeutic drug monitoring	4
P145	TPMT and NUDT15 genotype and azathioprine and mercaptopurine dose	Pharmacokinetics and therapeutic drug monitoring	5
P146	USE OF FAILURE MODES, EFFECTS AND CRITICALITY ANALYSIS (FMECA) TO IMPROVE SAFETY IN THE INJECTABLE CHEMOTHERAPY PRODUCTION PROCESS	Quality management	1
P147	ESOP's yellow hand: are the pharmaceutical laboratories really are devoting all the necessary?	Quality management	2
P148	Quality and economic value of returned unused oral targeted anticancer medication from patients and measures to reduce medication waste.	Quality management	3
P149	National Cancer Information System, Ireland – configuring a national drug file and regimen library	Quality management	4
P150	Improving the safety on the pathway of patients receiving CAR-T cells: risk analysis at the Pitié-Salpêtrière hospital	Quality management	5
P151	Destruction of chemotherapy preparations after non-compliant analytical control: what types of errors and for which molecules?	Quality management	6
P152	A simulation tool to evaluate experimental drugs preparation practices	Quality management	7
P153	Implementation of an Advanced Therapy Medical Product (ATMP, Tabelecleucel) in a University Teaching Hospital in France. Application of the Preliminary Risk Analysis Method	Quality management	8
P154	Implementation of the Advanced Therapy Medical Product (ATMP) Tisagenlecleucel in a University Teaching Hospital in France. Application of the Preliminary Risk Analysis Method	Quality management	9
P155	Securizing advanced therapy medicinal product (ATMP) tabeclleucel delivery	Quality management	10
P156	Securing the administration of chemotherapy prepared in syringes for administration by electric syringe pump	Quality management	11